Breaking News on Global Pharmaceutical Technology & Manufacturing

Mergers and acquisitions

Mergers and acquisitions

The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.

Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR-T

28-Aug-2017 - Gilead will add a late-stage CAR T-cell candidate and a facility in California capable of treating 5,000 patients per year through the $11.9bn deal.

AMRI set to be acquired by private equity

06-Jun-2017 - Private equity continues to make inroads in the contract research industry with two firms set to purchase AMRI in a deal worth $21.75 per share.


How Thermo Fisher buying Patheon could simplify pharma supply chains

15-May-2017 - Thermo Fisher Scientific is set to buy contract manufacturer Patheon, but what would this mean for the life science tech firm?

Looking to gain a foothold in Ireland? MSD puts shuttered site up for sale

28-Feb-2017 - Merck & Co. has put an Irish small molecule plant up for sale after ceasing production late last year.

Thermo Fisher bags single-use bioreactor tech partner Finesse

14-Feb-2017 - Thermo Fisher Scientific says it is buying Finesse Solutions, its long-term supplier of measurement and control solutions for bioprocessing applications.


J&J buying Actelion for $30bn, but should CMOs be concerned?

26-Jan-2017 - With no production sites of its own, we question whether Johnson & Johnson’s manufacturing network is likely to incorporate Actelion’s substantial product portfolio.

A 'small sale for MannKind' as it offloads Californian HQ and production site

25-Jan-2017 - MannKind Corporation has agreed to sell its headquarters and manufacturing site in Valencia, California to Rexford Industrial Realty for $17.3m.

Day 2

JP Morgan Conference: Trumpcare, moonshots and M&A

10-Jan-2017 - If you're not going to San Francisco, in-Pharmatechnologist brings you a smattering of the best tweets from the 35th Annual JP Morgan Healthcare Conference.

Out with the old, in with the new? Lonza sells peptide biz, Recipharm adds Indian ops

05-Jan-2017 - Recipharm receives approval to buy Kemwell’s Indian operations and PolyPeptides completes the acquisition of Lonza’s peptide business. Welcome to in-Pharmatechnologist’s 2017 M&A round-up.

Catalent: smaller firms set to struggle in capital intensive CMO space

09-Nov-2016 - Increasing regulatory burdens are increasing costs and will create fewer, bigger, and better players in the CDMO space, according to Catalent’s CEO.

Pfizer closing two UK manufacturing plants: 370 jobs at risk

09-Nov-2016 - Pfizer has earmarked two sites in the UK for closure, including an ex-Hospira aseptic plant in London it says would need ‘significant investment’ to remain open.

Cambrex bolstering API services through $25m PharmaCore acquisition

26-Sep-2016 - Cambrex will acquire clinical-scale API maker PharmaCore for $25m adding a standalone GMP facility in North Carolina approved to make Schedule II to V products.

Shire ends pacritinib development deal with CTI post Baxalta merger

20-Sep-2016 - Shire has abandoned its partnership on CTI BioPharma’s oral kinase inhibitor pacritinib seven months after deaths in a Phase III trial halted its clinical development.

Spain's Idifarma bolstered by investment from API maker Suanfarma

12-Sep-2016 - Spanish API maker Suanfarma has acquired a stake in contract manufacturer and spray-drying specialist Idifarma, boosting its international presence.

Piramal: $53m Ash Stevens addition ‘synergistic’ with ADC business

18-Aug-2016 - The acquisition of Ash Stevens and a US high potent API facility will bolster Piramal’s antibody-drug conjugate offerings, the Indian CDMO says.

Public Patheon's $2bn warchest may bolster biologics offering, analyst

17-Aug-2016 - Biomanufacturing demand will drive revenues for Patheon according to an Evercore ISI analyst, who has predicted the newly-listed CDMO will strengthen its capabilities through M&A.

Pfizer halts production at Hospira India plant slammed by regulators

09-Aug-2016 - Pfizer has temporarily halted production at a former-Hospira aseptic plant in Chennai, India after regulators observed manufacturing issues during an inspection in June.

News in brief

Biesterfield buys fellow API distributor Schütz

02-Aug-2016 - Biesterfeld says the acquisition of fellow Germany-based distributor Schütz strengthens the firm’s focus on specialty chemicals.

Pfizer takes axe to Hospira network, exiting 'under-utilised' Colorado plant

27-Jun-2016 - Over 100 Colorado jobs could be lost following Pfizer’s decision to exit a former Hospira API plant by 2019.

Monsanto bid may mean Bayer will cut pharma R&D spending, says analyst

31-May-2016 - The proposed $62bn merger with agrochemical firm Monsanto would jeopardise Bayer’s pharmaceutical business, according to a BMI Research analyst.

Pfizer, Anacor enter into merger agreement

18-May-2016 - Pfizer and Anacor Pharmaceuticals have entered into a definitive merger agreement under which Pfizer will acquire Anacor for approximately $5.2bn.

Endo takes axe to Par manufacting network: 740 jobs affected

12-May-2016 - Endo International says it intends to expedite a cost-saving plan by closing a manufacturing site in North Carolina and reducing headcount at another in Alabama.

Ferrer to add drug aerosol delivery tech through Alexza acquisition

11-May-2016 - Grupo Ferrer Internacional will acquire Alexza Pharmaceuticals for around $2m, adding the Staccato aerosol system to its drug delivery offerings.

AMRI acquires API business, expands into Europe

05-May-2016 - AMRI has acquired the Italy-based chemical company, Euticals, in a move that expands its API development and manufacturing business.

Biogen haemophilia spin-out to develop gene therapies and long-acting factors

04-May-2016 - The new entity will focus on a haemophilia pipeline utilising the XTEN half-life extension technology, bispecific antibodies and gene therapies.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...